Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study-Reference-Cited by-同舟云学术

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

Published:2021-04-05 Issue:3 Volume:27 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Reding Mark T.¹^ORCID,Pabinger Ingrid²^ORCID,Holme Pal Andre³,Poulsen Lone⁴,Negrier Claude⁵^ORCID,Chalasani Pavani⁶,Maas Enriquez Monika⁷,Wang Maria⁸,Meijer Karina⁹,Mancuso Maria Elisa¹⁰^ORCID,Lalezari Shadan¹¹

Affiliation:

1. Center for Bleeding and Clotting Disorders University of Minnesota Medical Center Minneapolis MN USA

2. University Clinic for Internal Medicine I Medical University of Vienna Vienna Austria

3. Department of Haematology Oslo University Hospital and Institute of Clinical Medicine, University of Oslo Oslo Norway

4. The Haemophilia Centre Aarhus University Hospital Aarhus Denmark

5. Hemophilia Comprehensive Care Center and Hematology Department Louis Pradel University Hospital Lyon France

6. Division of Hematology and Oncology University of Arizona Cancer Center Phoenix AZ USA

7. Bayer Wuppertal Germany

8. Bayer Whippany NJ USA

9. University Medical Center Groningen Groningen Netherlands

10. Center for Thrombosis and Haemorrhagic Diseases IRCCS Humanitas Clinical and Research Center Rozzano Italy

11. National Haemophilia Centre Chaim Sheba Medical Centre Tel Aviv University Tel Hashomer Israel

Funder

Bayer

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14297

Reference20 articles.

1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

2. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

3. Methods for individualising factor VIII dosing in prophylaxis

4. Practical aspects of extended half-life products for the treatment of haemophilia

5. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review;Drugs in R&D;2024-08-20

2. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII;Acta Haematologica;2024-04-23

3. Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada;Haemophilia;2024-02-20

4. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies;Research and Practice in Thrombosis and Haemostasis;2024-02

5. Advances and challenges in the purification of recombinant coagulation factors: A review;Journal of Chromatography A;2024-02